{"result": {"id": "0174cb1d-05fc-42bd-a611-1e24ad2ca8c8", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>PRIMARY ALDOSTERONISM<|>EVENT<|>Primary aldosteronism is a condition characterized by excessive production of aldosterone, leading to hypertension and low potassium levels. It is diagnosed through screening, confirmation, and subtyping steps, including the aldosterone-to-renin ratio (ARR) test and various confirmatory tests like the saline infusion test and captopril test.\")\n##\n(\"entity\"<|>ALDOSTERONE-TO-RENIN RATIO (ARR)<|>EVENT<|>The aldosterone-to-renin ratio (ARR) is a screening test for primary aldosteronism. It involves measuring aldosterone and renin levels, with specific cutoff values indicating the need for further confirmatory testing.\")\n##\n(\"entity\"<|>SALINE INFUSION TEST<|>EVENT<|>The saline infusion test is a confirmatory test for primary aldosteronism, where saline is administered intravenously to suppress aldosterone levels in normal individuals, but not in those with primary aldosteronism.\")\n##\n(\"entity\"<|>CAPTOPRIL TEST<|>EVENT<|>The captopril test is a confirmatory test for primary aldosteronism, where captopril is administered to observe the suppression of aldosterone levels in normal individuals, but not in those with primary aldosteronism.\")\n##\n(\"entity\"<|>FLUDROCORTISONE SUPPRESSION TEST<|>EVENT<|>The fludrocortisone suppression test is a confirmatory test for primary aldosteronism, but it is rarely used in some regions due to the unavailability of the drug.\")\n##\n(\"relationship\"<|>PRIMARY ALDOSTERONISM<|>ALDOSTERONE-TO-RENIN RATIO (ARR)<|>The aldosterone-to-renin ratio (ARR) is used as a screening tool for primary aldosteronism.<|>8)\n##\n(\"relationship\"<|>PRIMARY ALDOSTERONISM<|>SALINE INFUSION TEST<|>The saline infusion test is one of the confirmatory tests for primary aldosteronism.<|>8)\n##\n(\"relationship\"<|>PRIMARY ALDOSTERONISM<|>CAPTOPRIL TEST<|>The captopril test is one of the confirmatory tests for primary aldosteronism.<|>8)\n##\n(\"relationship\"<|>PRIMARY ALDOSTERONISM<|>FLUDROCORTISONE SUPPRESSION TEST<|>The fludrocortisone suppression test is a confirmatory test for primary aldosteronism, though rarely used in some regions.<|>6)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558784, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 591, "prompt_tokens": 2482, "total_tokens": 3073, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 690}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: �素的合成 ;③抑制组胺的合成及释放\t　一般停药后血压即可恢复正常。 需监测血钾水平\n麻黄素类\t麻黄素滴鼻剂 ,麻黄素与氯苯那敏、 苯海拉明等配伍\t　①直接激动肾上腺素 α和 β2 受体 ; ②间接促进 NE 神经递质的释放 ;③较显著的中枢兴奋作用\t应用 α受体阻滞剂、β受体阻滞剂\n　　注 :CCB为钙通道阻滞药;ACEI为血管紧张素转换酶抑制药;ARB为血管紧张素受体阻滞药;5-HT为 5-羟色胺;VEGF为血管内皮生长因子 ; RAS为肾素-血管紧张素系统;NE为去甲肾上腺素。\n\n\n　10.5.2  诊断流程   临床诊断流程包括筛查、确诊、分 型定侧三个步骤。\n　　筛查对象和主要指标 :血压超过 150/100mmHg、难  治性高血压、高血压合并自发性或利尿剂诱发低钾血症、 肾上腺意外瘤、一级亲属患原发性醛固酮增多症、睡眠呼  吸暂停综合征、排除因心脏结构性病变或甲状腺功能亢  进导致的心房颤动[712] 、早发高血压或心血管事件家族史  (<40岁) 。初诊高血压患者应考虑纳入原发性醛固酮增  多症的筛查。低钾血症不再是纳入筛查的必要条件[713] 。\n　　采用血醛固酮/肾素比值(aldosteronetoreninra- tio,ARR) [714] 作为筛查指标 。 肾素的测定方法目前  有肾素活性测定和直接肾素浓度测定 。筛查前应调整  使用对 RAS影响较小的降压药 ,换用对 ARR影响较  小的药 物(非 二 氢 吡 啶 类 CCB 和 α 受 体 阻 滞 剂) 。 MRA、利尿剂及甘草类药物需停用 4 周 , RAS抑制  剂、二氢吡啶类 CCB及 β受体阻滞剂需停药 2周 。如\n\n\n　服用上述激发肾素药物时肾素活性低于检测下限 , 同  时 ARR升高也可维持原有药物 。纠正低钾血症 , 维  持正常的钠盐摄入 。如果患者 ARR超过切点值 , 即  以肾素活 性 计 算 时 , ARR>30[醛 固 酮 单 位 ng/dL\n\n　或者以 肾 素 浓 度 计 算 时 , ARR> 3.7(醛 固 酮 单 位 为 ng/dL, 肾素浓度单位为 mU/L) ,且血浆醛固酮浓 度>15ng/dL,则进入确诊阶段。\n　　确诊试验 :主要有静脉生理盐水试验、卡托普利试 验、氟氢可的松抑制试验[713] 、高钠饮食试验 。氟氢可 的松抑制试验因国内缺乏此类药物而很少开展 。建议 联合使用≥1种以上的确诊方法 。对于血浆醛固酮浓 度>20ng/dL\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_5807512cadd7c32c5b6a03f436617da0c1dcc2a46588486209dfa301aa096ed4_v2"}